Moore Capital Management’s Novartis NVS Stock Holding History

Moore Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-110,000	Closed	-$9.07M	–	280
2020 Q1	$9.07M	Buy	+110,000	New	+$9.81M	0.38%	64
2014 Q3	–	Sell	-200,880	Closed	-$16.3M	–	481
2014 Q2	$16.3M	Buy	+200,880	New	+$15.8M	0.39%	65

Other funds holding NVS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Moore Capital Management's NVS Position: Q2 2020 in Review

Moore Capital Management sold out of Novartis (NVS) in Q2 2020, closing a stake of 110,000 shares — an estimated $9.07M sold.

Moore Capital Management first reported a position in NVS in Q2 2014 and held it in 2 quarters. The position peaked at $16.3M in Q2 2014. 1,128 funds tracked by Wall St. Rank hold NVS as of Q2 2020.

Moore Capital Management reported no remaining Novartis position as of Q2 2020 after selling out during the quarter.
Moore Capital Management sold 110,000 Novartis shares in Q2 2020, an estimated $9.07M.
Moore Capital Management first reported a position in Novartis in Q2 2014 and held it in 2 quarters.
Moore Capital Management's Novartis position peaked at $16.3M in Q2 2014.
1,128 funds tracked by Wall St. Rank held Novartis as of Q2 2020.

Based on Moore Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.